Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Christopher Bi

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Organic Letters|November 3, 2006
Studies on oxidopyrylium [5+2] cycloadditions: toward a general synthetic route to the C12-hydroxydaphnetoxinsPaul A Wender, F Christopher Bi, Nicole Buschmann, et al.
Drug Discovery Today|August 27, 2013
Driving external chemistry optimization via operations management principlesF Christopher Bi, Heather N Frost, Xiaolan Ling, et al.
Journal of the American Chemical Society|November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatinPaul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Science (New York, N.Y.)|October 9, 2010
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonistsBeili Wu, Ellen Y T Chien, Clifford D Mol, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Organic Letters|November 3, 2006
Studies on oxidopyrylium [5+2] cycloadditions: toward a general synthetic route to the C12-hydroxydaphnetoxinsPaul A Wender, F Christopher Bi, Nicole Buschmann, et al.
Drug Discovery Today|August 27, 2013
Driving external chemistry optimization via operations management principlesF Christopher Bi, Heather N Frost, Xiaolan Ling, et al.
Journal of the American Chemical Society|November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatinPaul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Science (New York, N.Y.)|October 9, 2010
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonistsBeili Wu, Ellen Y T Chien, Clifford D Mol, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Pageof 1